End-of-day quote
Korea S.E.
23:00:00 25/04/2024 BST
|
5-day change
|
1st Jan Change
|
426
KRW
|
-1.39%
|
|
+0.71%
|
+2.40%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
59,353
|
31,051
|
22,637
|
63,177
|
30,779
|
27,609
|
Enterprise Value (EV)
1 |
59,018
|
41,713
|
37,500
|
76,028
|
43,621
|
46,763
|
P/E ratio
|
-3.28
x
|
-1.65
x
|
13.7
x
|
-15.3
x
|
-3.96
x
|
-1.38
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.63
x
|
1.45
x
|
0.99
x
|
2.64
x
|
1.32
x
|
1.03
x
|
EV / Revenue
|
2.62
x
|
1.95
x
|
1.64
x
|
3.17
x
|
1.86
x
|
1.74
x
|
EV / EBITDA
|
-4.38
x
|
-4.47
x
|
9.44
x
|
-16.7
x
|
-9.15
x
|
-3.48
x
|
EV / FCF
|
-6.18
x
|
-6.16
x
|
-8.11
x
|
-16.6
x
|
-10.2
x
|
-13.1
x
|
FCF Yield
|
-16.2%
|
-16.2%
|
-12.3%
|
-6.02%
|
-9.83%
|
-7.63%
|
Price to Book
|
1.15
x
|
0.95
x
|
0.66
x
|
1.96
x
|
1.06
x
|
1.45
x
|
Nbr of stocks (in thousands)
|
57,759
|
57,759
|
57,747
|
60,747
|
65,767
|
66,367
|
Reference price
2 |
1,028
|
537.6
|
392.0
|
1,040
|
468.0
|
416.0
|
Announcement Date
|
19/03/19
|
20/03/20
|
19/03/21
|
18/03/22
|
21/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
22,541
|
21,442
|
22,854
|
23,951
|
23,396
|
26,878
|
EBITDA
1 |
-13,478
|
-9,335
|
3,972
|
-4,557
|
-4,766
|
-13,436
|
EBIT
1 |
-15,431
|
-11,131
|
2,879
|
-5,780
|
-6,046
|
-14,707
|
Operating Margin
|
-68.46%
|
-51.91%
|
12.6%
|
-24.13%
|
-25.84%
|
-54.72%
|
Earnings before Tax (EBT)
1 |
-15,360
|
-18,786
|
1,637
|
-4,179
|
-7,765
|
-21,398
|
Net income
1 |
-15,350
|
-18,764
|
1,647
|
-4,075
|
-7,383
|
-19,966
|
Net margin
|
-68.1%
|
-87.51%
|
7.21%
|
-17.01%
|
-31.56%
|
-74.28%
|
EPS
2 |
-313.0
|
-324.9
|
28.51
|
-68.17
|
-118.1
|
-301.0
|
Free Cash Flow
1 |
-9,544
|
-6,767
|
-4,626
|
-4,580
|
-4,287
|
-3,568
|
FCF margin
|
-42.34%
|
-31.56%
|
-20.24%
|
-19.12%
|
-18.32%
|
-13.28%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/19
|
20/03/20
|
19/03/21
|
18/03/22
|
21/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
10,662
|
14,863
|
12,852
|
12,842
|
19,154
|
Net Cash position
1 |
334
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-1.142
x
|
3.742
x
|
-2.82
x
|
-2.694
x
|
-1.426
x
|
Free Cash Flow
1 |
-9,544
|
-6,767
|
-4,626
|
-4,580
|
-4,287
|
-3,568
|
ROE (net income / shareholders' equity)
|
-31.1%
|
-44.2%
|
4.82%
|
-12.4%
|
-25%
|
-83.9%
|
ROA (Net income/ Total Assets)
|
-13.8%
|
-10.6%
|
3.17%
|
-6.35%
|
-6.84%
|
-17.2%
|
Assets
1 |
111,286
|
177,411
|
51,997
|
64,175
|
107,957
|
116,334
|
Book Value Per Share
2 |
890.0
|
566.0
|
594.0
|
531.0
|
441.0
|
287.0
|
Cash Flow per Share
2 |
155.0
|
49.40
|
42.70
|
84.90
|
56.10
|
35.40
|
Capex
1 |
6,790
|
1,584
|
1,448
|
867
|
916
|
1,458
|
Capex / Sales
|
30.12%
|
7.39%
|
6.33%
|
3.62%
|
3.92%
|
5.42%
|
Announcement Date
|
19/03/19
|
20/03/20
|
19/03/21
|
18/03/22
|
21/03/23
|
21/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +2.40% | 20.97M | | +12.07% | 128B | | -9.04% | 10.65B | | +0.91% | 8.82B | | +16.72% | 7.19B | | +25.15% | 4.99B | | +7.17% | 3.4B | | -1.36% | 3.03B | | -8.73% | 2.14B | | -10.15% | 2B |
Medical Devices & Implants
|